CovEpiAb contains 12 613 antibodies against HCoVs. Within this collection, 988 structures are available for 589 antibodies, and 6605 binding affinity records and 62962 neutralizing activity records were investigated. The binding and neutralization profiles of these antibodies against HCoVs and SARS-CoV-2 variants are listed here.

We conducted an analysis on antibody gene usage and employed Sankey plots to illustrate the utilization patterns of the top 50 most frequent V and J gene pairs in both antibody heavy and light chains. The heavy chain V and J human genes most commonly used are IGKV3-30, IGHV1-69, IGHJ4, IGHJ6, and the light chain V and J human genes most commonly used are IGKV1-39, IGKV3-20, IGKJ1 and IGLJ3.

We classify new coronavirus variants according to pango lineage and prevalence, including 64 currently circulating or previously circulating variants. The database includes the virological characteristics of these variants, as well as in vitro activity data of 108 therapeutics against the variants, including 55 vaccines, 34 neutralizing antibodies, and 22 plasma samples from recovered patients, with a total of 10,158 in vitro activity records. Analytical results indicate that recently identified Omicron subvariants, such as EG.5 and FL.1.5.1, exhibit greater reductions in in vitro activity against various therapeutic agents compared with other variants. The most significant reduction was observed in neutralizing antibodies.